13.42000 EUR
0.005
0.04%
Last update Dec 15, 8:13 AM CET
Main market
Day range
13.42000
13.42000
Previous close
13.42500
Open
13.42000
Access this stock data via API
Subscribe
Aurinia Pharmaceuticals Inc.
13.42
0.01
0.04%

Overview

Access /time_series data via our API — starting from the Basic plan.

Description

Aurinia Pharmaceuticals Inc. is a biotechnology company focused on the development and commercialization of novel therapies for the treatment of autoimmune diseases. The company's primary function is to advance therapeutic options that improve the lives of individuals suffering from debilitating autoimmune conditions. A standout feature of Aurinia Pharmaceuticals is its specialization in nephrology, which includes its flagship product designed to treat lupus nephritis, a severe manifestation of systemic lupus erythematosus impacting kidney function. Aurinia's research and development efforts concentrate on innovative drug platforms, leveraging scientific advancements to address unmet medical needs in the immune system disorders arena. As a key player in the biotech industry, Aurinia Pharmaceuticals contributes to significant advancements in personalized medicine and targeted therapy. By pushing the boundaries of conventional treatment options, the company plays a crucial role in expanding the horizons of autoimmune disease management within global healthcare markets.

About

CEO
Mr. Peter S. Greenleaf M.B.A.
Employees
130
Address
#140, 14315 – 118 Avenue
Suite 140
Edmonton, T5L 4S6, AB
Canada
Phone
250 744 2487
Instrument type
Common stock
Sector
Healthcare
Industry
Biotechnology
Country
Germany
MIC code
XBER
Access /profile data via our API — starting from the Grow plan.
Main market

Exchange is currently active.
Closing in 5 hours 55 minutes

14:04
00:00
08:00
20:00
23:59

Trading Hours (Monday - Friday):

Main market
08:00 - 20:00
All times are displayed in the Europe/Berlin timezone (CET, UTC+01:00).